Panoramic Capital LLC Makes New Investment in NeurAxis, Inc. $NRXS

Panoramic Capital LLC acquired a new position in shares of NeurAxis, Inc. (NASDAQ:NRXS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 115,000 shares of the company’s stock, valued at approximately $841,000. Panoramic Capital LLC owned 0.92% of NeurAxis at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of NRXS. Manatuck Hill Partners LLC purchased a new position in NeurAxis in the second quarter valued at $122,000. Citadel Advisors LLC increased its holdings in NeurAxis by 39.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock worth $110,000 after purchasing an additional 10,103 shares during the period. Money Concepts Capital Corp raised its position in NeurAxis by 566.6% in the 4th quarter. Money Concepts Capital Corp now owns 222,605 shares of the company’s stock valued at $1,011,000 after purchasing an additional 189,210 shares in the last quarter. Geode Capital Management LLC raised its position in NeurAxis by 48.8% in the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock valued at $343,000 after purchasing an additional 24,817 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in shares of NeurAxis in the 4th quarter valued at about $1,299,000. 11.77% of the stock is currently owned by institutional investors and hedge funds.

NeurAxis Stock Performance

Shares of NeurAxis stock opened at $5.96 on Thursday. NeurAxis, Inc. has a one year low of $2.21 and a one year high of $9.33. The company has a market cap of $74.85 million, a PE ratio of -3.24 and a beta of 1.49. The business has a 50-day simple moving average of $6.75 and a 200-day simple moving average of $6.80.

NeurAxis Company Profile

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.